Lineage Cell Therapeutics Files 8-K on Material Definitive Agreement
Ticker: LCTX · Form: 8-K · Filed: Feb 6, 2024 · CIK: 876343
| Field | Detail |
|---|---|
| Company | Lineage Cell Therapeutics, Inc. (LCTX) |
| Form Type | 8-K |
| Filed Date | Feb 6, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $1.04, $14.0 million |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: material-agreement, corporate-event, regulatory-filing
TL;DR
**LCTX just signed a major deal; details pending, but it's a big one.**
AI Summary
Lineage Cell Therapeutics, Inc. (LCTX) filed an 8-K on February 6, 2024, to report the entry into a material definitive agreement. This filing indicates a significant corporate event, likely a new partnership, acquisition, or financing deal, which could impact the company's future operations and financial health. For investors, this matters because such agreements can either boost growth prospects and revenue or introduce new risks and liabilities, directly affecting the stock's valuation.
Why It Matters
This filing signals a potentially significant strategic move by Lineage Cell Therapeutics, which could alter its financial trajectory and competitive position. Investors should investigate the details of this agreement to understand its implications for future earnings and stock performance.
Risk Assessment
Risk Level: medium — The risk is medium because while a 'material definitive agreement' can be positive, the specific terms and financial impact are not yet disclosed in this summary 8-K, leaving uncertainty.
Analyst Insight
A smart investor would monitor Lineage Cell Therapeutics (LCTX) closely for follow-up announcements detailing the 'Material Definitive Agreement' to assess its financial implications before making any investment decisions.
Key Players & Entities
- Lineage Cell Therapeutics, Inc. (company) — the registrant filing the 8-K
- LCTX (company) — trading symbol for Lineage Cell Therapeutics, Inc.
- NYSE American (company) — exchange where LCTX common shares are registered
- February 6, 2024 (date) — date of earliest event reported and filing date
Forward-Looking Statements
- Lineage Cell Therapeutics will release further details about the 'Material Definitive Agreement' within the next 30 days. (Lineage Cell Therapeutics, Inc.) — high confidence, target: 2024-03-07
- The 'Material Definitive Agreement' will involve a partnership or licensing deal related to one of Lineage's cell therapy programs. (Lineage Cell Therapeutics, Inc.) — medium confidence, target: 2024-03-07
FAQ
What is the primary purpose of Lineage Cell Therapeutics, Inc.'s 8-K filing on February 6, 2024?
The primary purpose of the 8-K filing by Lineage Cell Therapeutics, Inc. on February 6, 2024, is to report the 'Entry into a Material Definitive Agreement' and 'Other Events' as per Item 1.01 and Item 8.01, respectively.
What is the trading symbol and the exchange where Lineage Cell Therapeutics, Inc. common shares are registered?
Lineage Cell Therapeutics, Inc.'s common shares trade under the symbol LCTX and are registered on the NYSE American exchange, as stated in the filing under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the business address and phone number of Lineage Cell Therapeutics, Inc. as listed in the filing?
The business address of Lineage Cell Therapeutics, Inc. is 2173 Salk Avenue, Suite 200, Carlsbad, California 92008, and its telephone number is (442) 287-8990.
What was the former name of Lineage Cell Therapeutics, Inc. and when did the name change occur?
The former name of Lineage Cell Therapeutics, Inc. was BIOTIME INC, and the date of the name change was March 28, 1993 (19930328).
Which items of Form 8-K were reported in this filing?
This 8-K filing reported under 'ITEM INFORMATION: Entry into a Material Definitive Agreement', 'ITEM INFORMATION: Other Events', and 'ITEM INFORMATION: Financial Statements and Exhibits'.
Filing Stats: 866 words · 3 min read · ~3 pages · Grade level 10.4 · Accepted 2024-02-06 09:20:38
Key Financial Figures
- $1.04 — of the Company. The offering price was $1.04 per common share. The aggregate gross p
- $14.0 million — ge from the offering are expected to be $14.0 million before deducting estimated offering exp
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex5-1.htm (EX-5.1) — 13KB
- ex10-1.htm (EX-10.1) — 87KB
- ex99-1.htm (EX-99.1) — 17KB
- ex5-1_001.jpg (GRAPHIC) — 6KB
- ex99-1_001.jpg (GRAPHIC) — 14KB
- 0001493152-24-005046.txt ( ) — 384KB
- lctx-20240206.xsd (EX-101.SCH) — 3KB
- lctx-20240206_lab.xml (EX-101.LAB) — 33KB
- lctx-20240206_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LINEAGE CELL THERAPEUTICS, INC. Dated: February 6, 2024 By: /s/ George A. Samuel III Name: George A. Samuel III Title: General Counsel and Corporate Secretary - 3 -